Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

ELECTION OF EMPLOYEES' SUPERVISOR

AND

APPOINTMENT OF THE CHAIRMAN OF THE SUPERVISORY COMMITTEE

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the ''Company'') is pleased to announce that, according to the articles of association of the Company, Ms. Ren Qian (''Ms. Ren'') was elected as an employees' supervisor of the seventh session of the supervisory committee of the Company (the ''Supervisory Committee'') at the meeting of the employees' representatives held on 11 January 2018, and was appointed by the Supervisory Committee as the chairman of the seventh session of the Supervisory Committee. The biographical information of Ms. Ren is set out below:

Ms. Ren, aged 48. Ms. Ren joined the Company in May 2011 and served as the deputy general manager and general manager of audit department of the Company from May 2011 up to the date hereof. Prior to joining the Company, Ms. Ren served as an auditor of the audit department of Shanghai No.1 Department Store Company Limited* () (whereafter merged with Shanghai Bailian Group Company Limited* (), a company listed on the Shanghai Stock Exchange, stock code: 600827) and the manager of financial department of a subsidiary thereof from July 1991 to October 1999; the chief officer of the second division of audit department of China Worldbest Group Company Limited* () from November 1999 to April 2006; the assistant to director of Shanghai Zhongzhou Certified Public Accountants Company Limited* () from May 2006 to September 2008; the deputy general manager of audit department of Shanghai China Fortune Company Limited* () (a company listed on the Shanghai Stock Exchange, stock code: 600621) from October 2008 to April 2011. Ms. Ren graduated from Shanghai University of Finance and Economics* () with a bachelor degree in economics in July 1991, and graduated from The Chinese University of Hong Kong with a master degree in accounting in November 2016.

As at the date of this announcement, Ms. Ren has not entered into a service contract with the Company as a supervisor of the Company (the ''Supervisor''). The appointment of Ms. Ren as a Supervisor of the seventh session of the Supervisory Committee shall commence from 11 January 2018 and end on the expiration of term of the seventh session of the Supervisory Committee. The remuneration of Ms. Ren will be determined primarily based on the economic benefits received by the Company and by reference to other factors including his responsibilities and actual performance as well as the remuneration standards of the industry.

Ms. Ren has confirmed that, save as disclosed above, as at the date of this announcement, she does not have any relationship with any directors (the ''Directors''), senior management or substantial shareholders of the Company, and does not hold any other positions in the Company or any subsidiaries of the Company nor any other directorships in listed public companies in the last three years.

To the best knowledge of the Directors, as at the date of this announcement, Ms. Ren has personal interest in 17,250 A shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance, representing approximately 0.001% of the total number of issued A shares of the Company and approximately 0.001% of the total number of shares of the Company in issue. Save as disclosed above, Ms. Ren does not have any interests or short positions in any shares, underlying shares or debentures of the Company within the meaning of Part XV of the Securities and Futures Ordinance as at the date of this announcement.

Save as disclosed above, there is no other information required to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. There are no matters concerning Ms. Ren that need to be brought to the attention of the Shareholders.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Qiyu

Chairman

Shanghai, the People's Republic of China

11 January 2018

As at the date of this announcement, the executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang and Mr. Wu Yifang; the non-executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Ms. Kang Lan and Mr. Wang Can; and the independent non-executive directors of the Company are Mr. Cao Huimin, Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin and Mr. Wai Shiu Kwan Danny.

*

For identification purposes only

Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published this content on 11 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 11 January 2018 11:44:03 UTC.

Original documenthttp://www.fosunpharma.com/uploads/2018011173631.pdf

Public permalinkhttp://www.publicnow.com/view/6C8CA554DC8F93A40B2B110D429A362C001F1F0A